We are pleased to invite you to meet with Heat Biologics’ CEO, Jeff Wolf, and Lead Director, Dr. John Prendergast, Ph.D. who will participate in a series of investor forums and discussion across Germany on August 13-14, 2019. Heat management will meet with investors in Frankfurt, Dusseldorf, Stuttgart and Munich.
Additionally, the Company respectfully requests that all German shareholders contact their broker to immediately vote their Heat Biologics’ shares for the upcoming adjourned Annual Meeting of Shareholders to be held on August 22, 2019. Votes should be provided to your brokers as soon as possible. Please also notify your broker of the CUSIP# 42237K300 and verify the votes have been submitted to Clearstream, who in turn must process and submit your vote to the tabulator.
The approval of these two remaining proposals is critical for the Company to maintain its ongoing operations and to fulfil its listing requirements on NASDAQ. Heat’s Management and the Board encourage all shareholders to vote in favor of the two remaining proposals in order to meet the necessary voting thresholds.
Investors interested to attend the investor forums can register below. Venue details will be provided upon confirmation of registration.
|Dusseldorf||Tuesday, August 13||1:00 PM CET|
|Frankfurt||Tuesday, August 13||6:30 PM CET|
|Stuttgart||Wednesday, August 14||12:00 PM CET|
|Munich||Wednesday, August 14||6:30 PM CET|